Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment
Abstract Giant cell tumor of bone (GCTB) is an intermediate malignant bone tumor that is locally aggressive and rarely metastasizes. Denosumab, which is a receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor, can be used to treat GCTB. We focused on potential immunotherapy for GCTB...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/15e54e693f844c898b660c77acb51cda |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:15e54e693f844c898b660c77acb51cda |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:15e54e693f844c898b660c77acb51cda2021-12-02T17:55:13ZTumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment10.1038/s41598-021-94022-w2045-2322https://doaj.org/article/15e54e693f844c898b660c77acb51cda2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94022-whttps://doaj.org/toc/2045-2322Abstract Giant cell tumor of bone (GCTB) is an intermediate malignant bone tumor that is locally aggressive and rarely metastasizes. Denosumab, which is a receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor, can be used to treat GCTB. We focused on potential immunotherapy for GCTB and investigated the tumor microenvironment of GCTB. Programmed death-ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase 1 (IDO1) expression and signal-regulatory protein alpha (SIRPα), forkhead box P3 (FOXP3), and cluster of differentiation 8 (CD8) infiltration were assessed by immunohistochemical studies of 137 tumor tissues from 96 patients. Of the naive primary specimens, 28% exhibited PD-L1 expression and 39% exhibited IDO1 expression. There was significantly more SIRPα+, FOXP3+, and CD8+ cell infiltration in PD-L1- and IDO1-positive tumors than in PD-L1- and IDO1-negative tumors. The frequency of PD-L1 expression and SIRPα+ cell infiltration in recurrent lesions treated with denosumab was significantly higher than in primary lesions and recurrent lesions not treated with denosumab. PD-L1 expression and higher SIRPα+ cell infiltration were significantly correlated with shorter recurrence-free survival. PD-L1 and SIRPα immune checkpoint inhibitors may provide clinical benefit in GCTB patients with recurrent lesions after denosumab therapy.Yu TodaKenichi KohashiHidetaka YamamotoShin IshiharaYoshihiro ItoYosuke SusukiKengo KawaguchiDaisuke KiyozawaDai TakamatsuIzumi KinoshitaYuichi YamadaJunki MaeharaAtsushi KimuraSadafumi TamiyaKenichi TaguchiTomoya MatsunobuYoshihiro MatsumotoYasuharu NakashimaMasaaki MawatariYoshinao OdaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Yu Toda Kenichi Kohashi Hidetaka Yamamoto Shin Ishihara Yoshihiro Ito Yosuke Susuki Kengo Kawaguchi Daisuke Kiyozawa Dai Takamatsu Izumi Kinoshita Yuichi Yamada Junki Maehara Atsushi Kimura Sadafumi Tamiya Kenichi Taguchi Tomoya Matsunobu Yoshihiro Matsumoto Yasuharu Nakashima Masaaki Mawatari Yoshinao Oda Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment |
| description |
Abstract Giant cell tumor of bone (GCTB) is an intermediate malignant bone tumor that is locally aggressive and rarely metastasizes. Denosumab, which is a receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor, can be used to treat GCTB. We focused on potential immunotherapy for GCTB and investigated the tumor microenvironment of GCTB. Programmed death-ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase 1 (IDO1) expression and signal-regulatory protein alpha (SIRPα), forkhead box P3 (FOXP3), and cluster of differentiation 8 (CD8) infiltration were assessed by immunohistochemical studies of 137 tumor tissues from 96 patients. Of the naive primary specimens, 28% exhibited PD-L1 expression and 39% exhibited IDO1 expression. There was significantly more SIRPα+, FOXP3+, and CD8+ cell infiltration in PD-L1- and IDO1-positive tumors than in PD-L1- and IDO1-negative tumors. The frequency of PD-L1 expression and SIRPα+ cell infiltration in recurrent lesions treated with denosumab was significantly higher than in primary lesions and recurrent lesions not treated with denosumab. PD-L1 expression and higher SIRPα+ cell infiltration were significantly correlated with shorter recurrence-free survival. PD-L1 and SIRPα immune checkpoint inhibitors may provide clinical benefit in GCTB patients with recurrent lesions after denosumab therapy. |
| format |
article |
| author |
Yu Toda Kenichi Kohashi Hidetaka Yamamoto Shin Ishihara Yoshihiro Ito Yosuke Susuki Kengo Kawaguchi Daisuke Kiyozawa Dai Takamatsu Izumi Kinoshita Yuichi Yamada Junki Maehara Atsushi Kimura Sadafumi Tamiya Kenichi Taguchi Tomoya Matsunobu Yoshihiro Matsumoto Yasuharu Nakashima Masaaki Mawatari Yoshinao Oda |
| author_facet |
Yu Toda Kenichi Kohashi Hidetaka Yamamoto Shin Ishihara Yoshihiro Ito Yosuke Susuki Kengo Kawaguchi Daisuke Kiyozawa Dai Takamatsu Izumi Kinoshita Yuichi Yamada Junki Maehara Atsushi Kimura Sadafumi Tamiya Kenichi Taguchi Tomoya Matsunobu Yoshihiro Matsumoto Yasuharu Nakashima Masaaki Mawatari Yoshinao Oda |
| author_sort |
Yu Toda |
| title |
Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment |
| title_short |
Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment |
| title_full |
Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment |
| title_fullStr |
Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment |
| title_full_unstemmed |
Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment |
| title_sort |
tumor microenvironment in giant cell tumor of bone: evaluation of pd-l1 expression and sirpα infiltration after denosumab treatment |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/15e54e693f844c898b660c77acb51cda |
| work_keys_str_mv |
AT yutoda tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT kenichikohashi tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT hidetakayamamoto tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT shinishihara tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT yoshihiroito tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT yosukesusuki tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT kengokawaguchi tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT daisukekiyozawa tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT daitakamatsu tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT izumikinoshita tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT yuichiyamada tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT junkimaehara tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT atsushikimura tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT sadafumitamiya tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT kenichitaguchi tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT tomoyamatsunobu tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT yoshihiromatsumoto tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT yasuharunakashima tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT masaakimawatari tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment AT yoshinaooda tumormicroenvironmentingiantcelltumorofboneevaluationofpdl1expressionandsirpainfiltrationafterdenosumabtreatment |
| _version_ |
1718379090728189952 |